라임병 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 지역별 및 부문별 예측(2026-2033년)

Lyme Disease Market Summary

The global lyme disease market size was valued at USD 2.9 billion in 2025 and is projected to grow from USD 3.1 billion in 2026 to USD 5.8 billion by 2033, growing at a CAGR of 9.4% from 2026 to 2033. North America Lyme Disease market held the largest share of 43.5% of the global market in 2025. The market is experiencing substantial growth due to the increasing prevalence of tick-borne infections across North America and Europe.

Climate change, expanding tick habitats, and rising outdoor recreational activities have significantly contributed to the growing incidence of Lyme disease globally. In addition, greater public awareness regarding the health risks associated with tick exposure has encouraged early diagnosis and timely treatment adoption. Governments and public health organizations are also actively promoting surveillance programs and awareness campaigns to reduce disease burden. The rising number of reported Lyme disease cases has created strong demand for effective diagnostics and therapeutics, supporting market expansion. Furthermore, increasing healthcare expenditure and improved access to infectious disease management in developed countries continue to strengthen the commercial potential of the lyme disease market across both diagnostic and therapeutic segments globally.

Lyme disease market size and growth forecast (2023-2033)

Advancements in diagnostic technologies are another major factor driving the growth of the lyme disease market. Traditional serological testing methods are increasingly being complemented by molecular diagnostics and rapid point-of-care testing solutions that improve detection accuracy and reduce diagnosis time. Healthcare providers are adopting advanced diagnostic platforms to identify Lyme disease during its early stages, helping reduce long-term complications and treatment costs. In addition, growing investments by biotechnology and diagnostic companies in research and development activities are accelerating innovation within the market. The emergence of automated laboratory systems, multiplex assays, and biomarker-based diagnostic approaches is further enhancing market competitiveness. Increasing collaborations between research institutes, public health laboratories, and private companies are also contributing to technological advancements, ultimately supporting broader adoption of efficient Lyme disease testing solutions in both hospital and laboratory settings worldwide.

The therapeutics segment of the Lyme Disease market is also expanding steadily due to increasing demand for effective treatment options and supportive care solutions. Antibiotics such as tetracyclines, penicillins, and cephalosporins remain the primary standard of care, with oral therapies accounting for a significant share of prescriptions. However, growing recognition of Post-Treatment Lyme Disease Syndrome (PTLDS) has increased interest in supportive and symptom management therapies, creating new commercial opportunities within the market. Pharmaceutical companies are actively exploring combination therapies, novel anti-infective agents, and pipeline candidates to address unmet clinical needs associated with persistent symptoms and late-stage disease complications. Additionally, rising investments in infectious disease research and favorable government support for tick-borne disease management programs are accelerating therapeutic development activities. These factors collectively continue to strengthen long-term growth prospects for the global Lyme Disease market.

Global Lyme Disease Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global Lyme disease market report based on type, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Therapeutic
  • Drug Class
  • Tetracyclines
  • Penicillins
  • Cephalosporins
  • Macrolides
  • Other Anti-infective Therapies
  • Treatment Modality
  • Antibiotic Therapy
  • Supportive & Symptom Management
  • Route of Administration
  • Oral
  • Injectable / Intravenous
  • Disease Stage
  • Early-Stage Lyme Disease
  • Late-Stage Lyme Disease
  • Post-Treatment Lyme Disease Syndrome (PTLDS)
• Diagnostic
  • Test Type
  • Serological Testing
  • Molecular Diagnostics
  • Culture-based Diagnostics
  • Rapid & Point-of-Care Diagnostics
  • Sample Type
  • Blood & Serum Samples
  • Cerebrospinal Fluid (CSF)
  • Synovial Fluid
  • Tissue Biopsy Samples
  • End User
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Public Health Laboratories
  • Research Institutes
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Lyme Disease Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis

Chapter 4. Lyme Disease Market: Type Business Analysis

• 4.1. Type Market Share, 2025 & 2033
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
• 4.4. Therapeutic
  • 4.4.1. Therapeutic Market, 2021 - 2033 (USD Million)
  • 4.4.2. Drug Class
    • 4.4.2.1. Drug Class Market, 2021 - 2033 (USD Million)
    • 4.4.2.2. Tetracyclines
      • 4.4.2.2.1. Tetracyclines Market, 2021 - 2033 (USD Million)
    • 4.4.2.3. Penicillins
      • 4.4.2.3.1. Penicillins Market, 2021 - 2033 (USD Million)
    • 4.4.2.4. Cephalosporins
      • 4.4.2.4.1. Cephalosporins Market, 2021 - 2033 (USD Million)
    • 4.4.2.5. Macrolides
      • 4.4.2.5.1. Macrolides Market, 2021 - 2033 (USD Million)
    • 4.4.2.6. Other Anti-infective Therapies
      • 4.4.2.6.1. Other Anti-infective Therapies Market, 2021 - 2033 (USD Million)
  • 4.4.3. Treatment Modality
    • 4.4.3.1. Treatment Modality Market, 2021 - 2033 (USD Million)
    • 4.4.3.2. Antibiotic Therapy
      • 4.4.3.2.1. Antibiotic Therapy Market, 2021 - 2033 (USD Million)
    • 4.4.3.3. Supportive & Symptom Management
      • 4.4.3.3.1. Supportive & Symptom Management Market, 2021 - 2033 (USD Million)
  • 4.4.4. Route of Administration
    • 4.4.4.1. Route of Administration Market, 2021 - 2033 (USD Million)
    • 4.4.4.2. Oral
      • 4.4.4.2.1. Oral Market, 2021 - 2033 (USD Million)
    • 4.4.4.3. Injectable / Intravenous
      • 4.4.4.3.1. Injectable / Intravenous Market, 2021 - 2033 (USD Million)
  • 4.4.5. Disease Stage
    • 4.4.5.1. Disease Stage Market, 2021 - 2033 (USD Million)
    • 4.4.5.2. Early-Stage Lyme Disease
      • 4.4.5.2.1. Early-Stage Lyme Disease Market, 2021 - 2033 (USD Million)
    • 4.4.5.3. Late-Stage Lyme Disease
      • 4.4.5.3.1. Late-Stage Lyme Disease Market, 2021 - 2033 (USD Million)
    • 4.4.5.4. Post-Treatment Lyme Disease Syndrome (PTLDS)
      • 4.4.5.4.1. Post-Treatment Lyme Disease Syndrome (PTLDS) Market, 2021 - 2033 (USD Million)
• 4.5. Diagnostic
  • 4.5.1. Diagnostic Market, 2021 - 2033 (USD Million)
  • 4.5.2. Test Type
    • 4.5.2.1. Test Type Market, 2021 - 2033 (USD Million)
    • 4.5.2.2. Serological Testing
      • 4.5.2.2.1. Serological Testing Market, 2021 - 2033 (USD Million)
    • 4.5.2.3. Molecular Diagnostics
      • 4.5.2.3.1. Molecular Diagnostics Market, 2021 - 2033 (USD Million)
    • 4.5.2.4. Culture-based Diagnostics
      • 4.5.2.4.1. Culture-based Diagnostics Market, 2021 - 2033 (USD Million)
    • 4.5.2.5. Rapid & Point-of-Care Diagnostics
      • 4.5.2.5.1. Rapid & Point-of-Care Diagnostics Market, 2021 - 2033 (USD Million)
  • 4.5.3. Sample Type
    • 4.5.3.1. Sample Type Market, 2021 - 2033 (USD Million)
    • 4.5.3.2. Blood & Serum Samples
      • 4.5.3.2.1. Blood & Serum Samples Market, 2021 - 2033 (USD Million)
    • 4.5.3.3. Cerebrospinal Fluid (CSF)
      • 4.5.3.3.1. Cerebrospinal Fluid (CSF) Market, 2021 - 2033 (USD Million)
    • 4.5.3.4. Synovial Fluid
      • 4.5.3.4.1. Synovial Fluid Market, 2021 - 2033 (USD Million)
    • 4.5.3.5. Tissue Biopsy Samples
      • 4.5.3.5.1. Tissue Biopsy Samples Market, 2021 - 2033 (USD Million)
  • 4.5.4. End User
    • 4.5.4.1. End User Market, 2021 - 2033 (USD Million)
    • 4.5.4.2. Hospitals & Clinics
      • 4.5.4.2.1. Hospitals & Clinics Market, 2021 - 2033 (USD Million)
    • 4.5.4.3. Diagnostic Laboratories
      • 4.5.4.3.1. Diagnostic Laboratories Market, 2021 - 2033 (USD Million)
    • 4.5.4.4. Public Health Laboratories
      • 4.5.4.4.1. Public Health Laboratories Market, 2021 - 2033 (USD Million)
    • 4.5.4.5. Research Institutes
      • 4.5.4.5.1. Research Institutes Market, 2021 - 2033 (USD Million)

Chapter 5. Lyme Disease Market: Regional Estimates & Trend Analysis

• 5.1. Regional Market Share Analysis, 2025 & 2033
• 5.2. Regional Market Dashboard
• 5.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 5.4. North America
  • 5.4.1. North America Lyme Disease Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 5.4.2. U.S.
    • 5.4.2.1. Key Country Dynamics
    • 5.4.2.2. Target Disease Prevalence
    • 5.4.2.3. Regulatory Framework
    • 5.4.2.4. Reimbursement Framework
    • 5.4.2.5. U.S. Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Canada
    • 5.4.3.1. Key Country Dynamics
    • 5.4.3.2. Target Disease Prevalence
    • 5.4.3.3. Regulatory Framework
    • 5.4.3.4. Reimbursement Framework
    • 5.4.3.5. Canada Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.4. Mexico
    • 5.4.4.1. Key Country Dynamics
    • 5.4.4.2. Target Disease Prevalence
    • 5.4.4.3. Regulatory Framework
    • 5.4.4.4. Reimbursement Framework
    • 5.4.4.5. Mexico Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Europe
  • 5.5.1. Europe Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. UK
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Target Disease Prevalence
    • 5.5.2.3. Regulatory Framework
    • 5.5.2.4. Reimbursement Framework
    • 5.5.2.5. Uk Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. Germany
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Target Disease Prevalence
    • 5.5.3.3. Regulatory Framework
    • 5.5.3.4. Reimbursement Framework
    • 5.5.3.5. Germany Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.4. France
    • 5.5.4.1. Key Country Dynamics
    • 5.5.4.2. Target Disease Prevalence
    • 5.5.4.3. Regulatory Framework
    • 5.5.4.4. Reimbursement Framework
    • 5.5.4.5. France Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.5. Italy
    • 5.5.5.1. Key Country Dynamics
    • 5.5.5.2. Target Disease Prevalence
    • 5.5.5.3. Regulatory Framework
    • 5.5.5.4. Reimbursement Framework
    • 5.5.5.5. Italy Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.6. Spain
    • 5.5.6.1. Key Country Dynamics
    • 5.5.6.2. Target Disease Prevalence
    • 5.5.6.3. Regulatory Framework
    • 5.5.6.4. Reimbursement Framework
    • 5.5.6.5. Spain Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.7. Denmark
    • 5.5.7.1. Key Country Dynamics
    • 5.5.7.2. Target Disease Prevalence
    • 5.5.7.3. Regulatory Framework
    • 5.5.7.4. Reimbursement Framework
    • 5.5.7.5. Denmark Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.8. Sweden
    • 5.5.8.1. Key Country Dynamics
    • 5.5.8.2. Target Disease Prevalence
    • 5.5.8.3. Regulatory Framework
    • 5.5.8.4. Reimbursement Framework
    • 5.5.8.5. Sweden Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.9. Norway
    • 5.5.9.1. Key Country Dynamics
    • 5.5.9.2. Target Disease Prevalence
    • 5.5.9.3. Regulatory Framework
    • 5.5.9.4. Reimbursement Framework
    • 5.5.9.5. Norway Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Asia Pacific
  • 5.6.1. Asia Pacific Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.2. Japan
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Target Disease Prevalence
    • 5.6.2.3. Regulatory Framework
    • 5.6.2.4. Reimbursement Framework
    • 5.6.2.5. Japan Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.3. China
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Target Disease Prevalence
    • 5.6.3.3. Regulatory Framework
    • 5.6.3.4. Reimbursement Framework
    • 5.6.3.5. China Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.4. India
    • 5.6.4.1. Key Country Dynamics
    • 5.6.4.2. Target Disease Prevalence
    • 5.6.4.3. Regulatory Framework
    • 5.6.4.4. Reimbursement Framework
    • 5.6.4.5. India Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.5. Australia
    • 5.6.5.1. Key Country Dynamics
    • 5.6.5.2. Target Disease Prevalence
    • 5.6.5.3. Regulatory Framework
    • 5.6.5.4. Reimbursement Framework
    • 5.6.5.5. Australia Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.6. South Korea
    • 5.6.6.1. Key Country Dynamics
    • 5.6.6.2. Target Disease Prevalence
    • 5.6.6.3. Regulatory Framework
    • 5.6.6.4. Reimbursement Framework
    • 5.6.6.5. South Korea Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.7. Thailand
    • 5.6.7.1. Key Country Dynamics
    • 5.6.7.2. Target Disease Prevalence
    • 5.6.7.3. Regulatory Framework
    • 5.6.7.4. Reimbursement Framework
    • 5.6.7.5. Thailand Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Latin America
  • 5.7.1. Latin America Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7.2. Brazil
    • 5.7.2.1. Key Country Dynamics
    • 5.7.2.2. Target Disease Prevalence
    • 5.7.2.3. Regulatory Framework
    • 5.7.2.4. Reimbursement Framework
    • 5.7.2.5. Brazil Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7.3. Argentina
    • 5.7.3.1. Key Country Dynamics
    • 5.7.3.2. Target Disease Prevalence
    • 5.7.3.3. Regulatory Framework
    • 5.7.3.4. Reimbursement Framework
    • 5.7.3.5. Argentina Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Middle East and Africa
  • 5.8.1. Middle East and Africa Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8.2. South Africa
    • 5.8.2.1. Key Country Dynamics
    • 5.8.2.2. Target Disease Prevalence
    • 5.8.2.3. Regulatory Framework
    • 5.8.2.4. Reimbursement Framework
    • 5.8.2.5. South Africa Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8.3. Saudi Arabia
    • 5.8.3.1. Key Country Dynamics
    • 5.8.3.2. Target Disease Prevalence
    • 5.8.3.3. Regulatory Framework
    • 5.8.3.4. Reimbursement Framework
    • 5.8.3.5. Saudi Arabia Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8.4. UAE
    • 5.8.4.1. Key Country Dynamics
    • 5.8.4.2. Target Disease Prevalence
    • 5.8.4.3. Regulatory Framework
    • 5.8.4.4. Reimbursement Framework
    • 5.8.4.5. UAE Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8.5. Kuwait
    • 5.8.5.1. Key Country Dynamics
    • 5.8.5.2. Target Disease Prevalence
    • 5.8.5.3. Regulatory Framework
    • 5.8.5.4. Reimbursement Framework
    • 5.8.5.5. Kuwait Lyme Disease Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. Pfizer Inc.
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial Performance
    • 6.5.1.3. Product Benchmarking
    • 6.5.1.4. Strategic Initiatives
  • 6.5.2. GSK plc
    • 6.5.2.1. Overview
    • 6.5.2.2. Financial Performance
    • 6.5.2.3. Product Benchmarking
    • 6.5.2.4. Strategic Initiatives
  • 6.5.3. Sanofi S.A.
    • 6.5.3.1. Overview
    • 6.5.3.2. Financial Performance
    • 6.5.3.3. Product Benchmarking
    • 6.5.3.4. Strategic Initiatives
  • 6.5.4. Merck & Co., Inc.
    • 6.5.4.1. Overview
    • 6.5.4.2. Financial Performance
    • 6.5.4.3. Product Benchmarking
    • 6.5.4.4. Strategic Initiatives
  • 6.5.5. F. Hoffmann-La Roche Ltd.
    • 6.5.5.1. Overview
    • 6.5.5.2. Financial Performance
    • 6.5.5.3. Product Benchmarking
    • 6.5.5.4. Strategic Initiatives
  • 6.5.6. Abbott Laboratories
    • 6.5.6.1. Overview
    • 6.5.6.2. Financial Performance
    • 6.5.6.3. Product Benchmarking
    • 6.5.6.4. Strategic Initiatives
  • 6.5.7. Thermo Fisher Scientific Inc.
    • 6.5.7.1. Overview
    • 6.5.7.2. Financial Performance
    • 6.5.7.3. Product Benchmarking
    • 6.5.7.4. Strategic Initiatives
  • 6.5.8. bioMerieux SA
    • 6.5.8.1. Overview
    • 6.5.8.2. Financial Performance
    • 6.5.8.3. Product Benchmarking
    • 6.5.8.4. Strategic Initiatives
  • 6.5.9. Bio-Rad Laboratories, Inc.
    • 6.5.9.1. Overview
    • 6.5.9.2. Financial Performance
    • 6.5.9.3. Product Benchmarking
    • 6.5.9.4. Strategic Initiatives
  • 6.5.10. DiaSorin S.p.A.
    • 6.5.10.1. Overview
    • 6.5.10.2. Financial Performance
    • 6.5.10.3. Product Benchmarking
    • 6.5.10.4. Strategic Initiatives